## Diabetes TrialNet CTLA-4 Ig Study NEUROLOGIC ASSESSMENT FORM

Form CTL22

01 JUNE 2008 Version 1.0 Page 1 of 1

				Page 1 of 1
Site Number:	Screening ID:		Participant Letters:	
	icipants enrolled prior t eline Visit prior to rando	o the addition of the ne	eurological assessmen	t
A. VISIT INFORMATION				
1. Was a neurologic assessmer If YES,	nt completed at this visit?			Y N
a. Date of assessment:			DAY MONTH	/
of the neurological of Baseline neurological of randomization for no End of treatment is	assessment (performed d assessment) ic assessment (performed	during the Screening or		the addition
$\begin{array}{c cccc} \square_0 & Baseline & \square_1 \\ \square_1 & Visit 1 & \square_2 \\ \square_3 & Visit 2 & \square_3 \\ \square_4 & Visit 3 & \square_4 \\ \square_5 & Visit 5 & \square_6 \\ \end{array}$	☐ 8  Visit 8 ☐ 9  Visit 9 ☐ 10  Visit 10 ☐ 11  Visit 11 ☐ 12  Visit 12 ☐ 13  Visit 13 ☐ 14  Visit 14 ☐ 15  Visit 15 ☐ 16  Visit 16	☐ 17 Visit 17 ☐ 18 Visit 18 ☐ 19 Visit 19 ☐ 20 Visit 20 ☐ 21 Visit 21 ☐ 22 Visit 22 ☐ 23 Visit 23 ☐ 24 Visit 24 ☐ 25 Visit 25	☐ 26 Visit 26 ☐ 27 Visit 27	
B. ASSESSMENT INFORMA	ATION			
1. Were there any clinically sig	gnificant abnormalities?			Y N
<ul> <li>If YES,</li> <li>If baseline assessment and clinically significant abnormalities noted, participant is <u>NOT ELIGIBLE</u> for study participation.</li> <li>If initial or follow-up assessment and clinically significant abnormalities noted, complete Adverse Event Report Form (CTL13) and refer to Neurologist for further evaluation.</li> </ul>				
	Initials (first, mid	dle, last) of person comp Date form completed	, , ,	F M L